Financial Comparison: Rhythm Pharmaceuticals (NASDAQ:RYTM) vs. BGM Group (NASDAQ:BGM)

BGM Group (NASDAQ:BGM) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Risk and Volatility

BGM Group has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500.

Profitability

This table compares BGM Group and Rhythm Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Rhythm Pharmaceuticals	-110.32%	-433.21%	-46.38%

Analyst Ratings

This is a summary of current ratings and target prices for BGM Group and Rhythm Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1	0	0	0	1.00
Rhythm Pharmaceuticals	2	1	14	1	2.78

Rhythm Pharmaceuticals has a consensus price target of $131.29, suggesting a potential upside of 33.87%. Given Rhythm Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than BGM Group.

Valuation and Earnings

This table compares BGM Group and Rhythm Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$25.10 million	4.26	-$1.44 million	N/A	N/A
Rhythm Pharmaceuticals	$174.33 million	37.54	-$260.60 million	($3.10)	-31.64

BGM Group has higher earnings, but lower revenue than Rhythm Pharmaceuticals.

Summary

Rhythm Pharmaceuticals beats BGM Group on 7 of the 11 factors compared between the two stocks.

About BGM Group

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil’s chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People’s Republic of China.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.